Goldman Sachs Rates Johnson & Johnson a Buy, Citing Pipeline Strength and Policy Tailwinds

Johnson & Johnson (NYSE:JNJ) ranks among the best set-it-and-forget-it stocks to buy. Asad Haider, a Goldman Sachs analyst, remained optimistic about Johnson & Johnson (NYSE:JNJ) shares, rating it as a Buy on June 5. The analyst noted several factors that lead to the update.

Goldman Sachs Rates Johnson & Johnson a Buy, Citing Pipeline Strength and Policy Tailwinds

Pixabay/Public Domain

Similar to its industry peers, the company demonstrates a proactive approach to navigating regulatory environments by participating in policy discussions with the administration. This could result in positive outcomes in areas such as 340B reform and PBM.

Johnson & Johnson’s innovation skills are further demonstrated by the company’s pharmaceutical pipeline achievements, including the encouraging Carvykti data and the expected approval of TAR-200. The company’s strategic move from Stelara to Tremfya and its investments in commercial fulfillment further highlight its commitment to preserving a dominant market position.

Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.